Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation
about
Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routesImmature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation.Current Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionPreclinical efficacy of a virus-like particle-based vaccine against avian influenza H5N1Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cellsVirus like particle-based vaccines against emerging infectious disease viruses.Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches.HIV-1 Gag-virus-like particles inhibit HIV-1 replication in dendritic cells and T cells through IFN-α-dependent upregulation of APOBEC3G and 3F.Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation.Immunogenomics and systems biology of vaccines.Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and MacaquesSelected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles.Abrogation of contaminating RNA activity in HIV-1 Gag VLPs.Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles.Effects of adjuvants on IgG subclasses elicited by virus-like particles.Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteinsImmunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.Molecular immune signatures of HIV-1 vaccines in human PBMCsClarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments.Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles.Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolateInduction of mucosal immunity through systemic immunization: Phantom or reality?Assessment of mucosal immunity to HIV-1.Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.Insect cell technology is a versatile and robust vaccine manufacturing platform.Developments in virus-like particle-based vaccines for infectious diseases and cancer.Developments in virus-like particle-based vaccines for HIV.VLPs and particle strategies for cancer vaccines.Systems vaccinology for cancer vaccine development.Short communication: limited induction of IL-10 in PBMCs from HIV-infected subjects treated with HIV-VLPs.Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.Canine parvovirus VP2 protein expressed in silkworm pupae self-assembles into virus-like particles with high immunogenicity.
P2860
Q22241377-E5930BC1-C10A-4319-A5D2-9E4082BE5FB0Q25257050-5BB688AE-D67B-4CCE-A302-AA793C233970Q26775082-FEF3DE27-76E4-44D0-BAB5-B2D7AA26ABC1Q28247277-86F15753-DBB8-4703-802F-66B4B176869FQ28732043-02209D3E-691B-4221-AF7B-B99900216D9BQ30249025-5736C151-0CE0-4B77-8CD1-075806C4EA82Q30392083-802EF105-9881-4454-93C5-E8A784E62285Q30418622-941695EB-6A5A-4C76-A28D-43F9DFC3E884Q33326902-3F5311F9-9B30-4BCF-8DF2-C7F6C1049008Q33350387-526687FE-79B7-4ED8-8122-F5FA39F47000Q33558475-BE51203A-0D29-4F20-B631-86CE4993B34CQ33683203-2C883B1A-5B2C-46E8-A303-37D4AD5AA87CQ34984724-E440524F-2BD0-41FE-9038-8A2055C44C12Q34993838-4A384364-4871-43D6-A56A-1D298703FC2EQ35112676-D561950E-D334-4830-80B9-F9719390411AQ35181739-8E806695-2D98-4A18-89AA-F65EE02037CCQ35478282-4208DAED-9679-4A13-AA8D-5715B7120214Q35635302-AD298B08-C757-4C55-83C7-B2E1E5438965Q35848642-B67FF684-E051-4043-9439-A07E841FDFB1Q35985896-E35793E1-4E04-481A-AA53-BE8C1CA6FE7CQ36017750-21518835-9E84-49A3-AFB4-815AD310583CQ36099119-90E7BAC8-B10E-4A55-A112-E758B995D09CQ36149102-042E1F70-E46F-437A-B2EF-8987E527FD91Q36155445-50DB415B-9ADB-4573-AA9E-9BD5049D0A88Q36162887-7DDF3DAC-EB28-4B73-B039-B04F0ACDBDB9Q36780136-F01592A9-B8FE-4854-955E-1E1F8B698554Q36943319-42C98B71-9E8C-4D3A-AA1C-B90BD3E66492Q37033232-B90EBFA6-FEA8-4860-9555-072612D23BA3Q37060319-510C17F4-87CB-4A80-BA6D-CF43196E358EQ37130744-0DE415DE-48B9-41FE-B251-9FDDF0004ECFQ37724856-19750794-A1F7-471F-B7BA-1D9027D5CB76Q37834097-E7BF5AC8-401A-4E25-ABBE-6D52E50236F0Q37909427-B35E549E-8757-4133-BFAD-53D629734CF6Q37951525-8D5A1954-3B38-4494-8D17-2F3182B7F695Q38081965-2AADBACE-A66E-4813-BA4D-B77A0D8491F9Q38152475-4B58055B-87DB-44DF-AE58-ADBC1046D2A5Q38207141-8EF27303-7E9E-4DB8-A8EA-FDD8C9F1172CQ38874078-EA8358AD-DD7E-49B3-B389-3379BB34BD10Q38879108-D4F076E1-ED0F-4217-98C6-3BC925A26947Q41877558-7EC368BF-183C-4E4E-A19B-6A7FFCC865D9
P2860
Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Induction of systemic and muco ...... ifferent routes of inoculation
@ast
Induction of systemic and muco ...... ifferent routes of inoculation
@en
type
label
Induction of systemic and muco ...... ifferent routes of inoculation
@ast
Induction of systemic and muco ...... ifferent routes of inoculation
@en
prefLabel
Induction of systemic and muco ...... ifferent routes of inoculation
@ast
Induction of systemic and muco ...... ifferent routes of inoculation
@en
P2093
P2860
P1433
P1476
Induction of systemic and muco ...... ifferent routes of inoculation
@en
P2093
Biryahwaho B
Buonaguro FM
Buonaguro L
Visciano ML
P2860
P304
P356
10.1128/JVI.79.11.7059-7067.2005
P577
2005-06-01T00:00:00Z